Heat Biologics, Inc. (HTBX) Short Interest Down 41.6% in November
Heat Biologics, Inc. (NASDAQ:HTBX) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 834,426 shares, a decrease of 41.6% from the November 15th total of 1,427,590 shares. Approximately 2.5% of the shares of the stock are short sold. Based on an average daily volume of 595,292 shares, the short-interest ratio is currently 1.4 days.
Separately, Griffin Securities started coverage on shares of Heat Biologics in a research report on Tuesday, September 12th. They set a “buy” rating and a $2.25 target price on the stock.
A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. boosted its holdings in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 661,388 shares of the biopharmaceutical company’s stock after buying an additional 70,290 shares during the period. Vanguard Group Inc. owned approximately 1.86% of Heat Biologics worth $403,000 as of its most recent SEC filing. 8.37% of the stock is currently owned by institutional investors and hedge funds.
Heat Biologics (NASDAQ:HTBX) last announced its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. Heat Biologics had a negative net margin of 1,184.92% and a negative return on equity of 149.69%. The business had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.50 million. equities analysts forecast that Heat Biologics will post -0.38 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Heat Biologics, Inc. (HTBX) Short Interest Down 41.6% in November” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/16/heat-biologics-inc-htbx-short-interest-down-41-6-in-november.html.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.